Epigenetic inhibitors for cancer treatment

Int Rev Cell Mol Biol. 2024;383:89-144. doi: 10.1016/bs.ircmb.2023.06.003. Epub 2023 Jul 18.ABSTRACTEpigenetics is a heritable and reversible modification that occurs independent of the alteration of primary DNA sequence but remarkably affects genetic expression. Aberrant epigenetic regulators are frequently observed in cancer progression not only influencing the behavior of tumor cells but also the tumor-associated microenvironment (TME). Increasing evidence has shown their great potential as biomarkers to predict clinical outcomes and chemoresistance. Hence, targeting the deregulated epigenetic regulators would be a compelling strategy for cancer treatment. So far, current epigenetic drugs have shown promising efficacy in both preclinical trials and clinical treatment of cancer, which encourages research discoveries on the development of novel epigenetic inhibitors either from natural compounds or artificial synthesis. However, only a few have been approved by the FDA, and more effort needs to be put into the related research. This chapter will update the applications and latest progress of epigenetic inhibitors in cancer treatment and provide prospects for the future development of epigenetic drugs.PMID:38359972 | DOI:10.1016/bs.ircmb.2023.06.003
Source: International Review of Cell and Molecular Biology - Category: Cytology Authors: Source Type: research